Study for the correlation between the efficacy of navuzumab and immunity in patients with non-small cell lung cancer

Prospective study for the correlation between Nivolumab efficacy and immune complexity in patients with advanced non-small cell lung cancer after first-line treatment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1900022077

Enrollment

Unknown

Registered

2019-03-23

Start date

2019-04-20

Completion date

Unknown

Last updated

2019-03-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Gold Standard:full length TCR mRNA fragment sequence

Index test:Methods:&#32

TCR&#32

library&#32

construction

cell&#32

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. stage IIIb/IV NSCLC patients with advanced chemotherapy; 2. has not received immunotherapy with other antibody drugs before; 3. the expected survival time is more than 3 months.

Exclusion criteria

Exclusion criteria: (1) Subjects eventually diagnosed as other diseases, including pleural disease, mediastinal disease, chest wall tumors, etc.; (2) Subjects gave up surgery and related examinations for various reasons, and ultimately could not obtain pathological or cytological findings; (3) The clinical evaluator could not be completed because the physical condition was not related to the examination, refused to be examined, or was interrupted for other reasons.

Design outcomes

Primary

Measure	Time frame
TCR diversity;	—

Countries

China

Contacts

Public ContactLI LIU

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

zhangkai8104@163.com+86 027-85872015

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026